As semaglutide and its GLP-1 receptor agonist relatives become among the most widely prescribed drugs on the planet, an underappreciated trade-off is emerging: a cluster of ocular complications that ranges from accelerated diabetic retinopathy to a rare but potentially blinding optic nerve condition. For the millions of adults taking these agents, understanding the eye-specific risk profile is no longer peripheral.
The clinical picture is nuanced. Data from the SUSTAIN-6 trial revealed a statistically significant elevation in diabetic retinopathy complications among semaglutide users, most pronounced in patients who already had retinopathy at baseline and who experienced rapid HbA1c reductions — a phenomenon historically called "early worsening" and attributed to sudden shifts in retinal perfusion. The LEADER and REWIND trials, studying liraglutide and dulaglutide respectively, did not replicate this signal, implying agent-specific rather than class-wide risk. More recently, pharmacoepidemiologic analyses and pharmacovigilance databases have flagged nonarteritic anterior ischemic optic neuropathy (NAION) — an infarction of the optic nerve head — as a very rare but serious adverse event, serious enough for the European Medicines Agency to formally classify it as such. Paradoxically, some real-world datasets suggest GLP-1 receptor agonists may reduce rates of neovascular age-related macular degeneration and diabetic macular edema, though those findings remain inconsistent across studies.
This review arrives at a critical inflection point. The proposed mechanisms — abrupt metabolic recalibration, vascular dysregulation, and direct GLP-1 receptor activity on retinal and optic-nerve tissue — remain incompletely characterized, which complicates risk stratification. From a population-health standpoint, the absolute risk of NAION appears low, but given the massive and growing user base for these agents, even rare event rates translate into substantial case numbers. The most important limitation here is confounding: patients on GLP-1 receptor agonists typically carry heavier burdens of vascular disease and pre-existing eye pathology, making causal attribution genuinely difficult. This is best characterized as an important confirmatory signal requiring prospective ophthalmologic surveillance protocols, particularly for patients with pre-existing retinopathy or optic nerve vulnerability.